Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

76.74
+0.15000.20%
Volume:162.55K
Turnover:12.47M
Market Cap:15.03B
PE:-21.50
High:77.45
Open:76.61
Low:76.41
Close:76.59
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.32
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.97
PE(LYR):-20.27

Loading ...

BRIEF-BridgeBio Pharma Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
May 08

BridgeBio Pharma Inc: Prospectus Supplement Covering Offering of up to $500 Mln of Common Stock

THOMSON REUTERS
·
May 08

Analysts Offer Insights on Healthcare Companies: Vericel (VCEL) and BridgeBio Pharma (BBIO)

TIPRANKS
·
May 08

BridgeBio Pharma posts corporate presentation outlining rare-disease pipeline, commercial strategy

Reuters
·
May 08

BridgeBio Pharma Q1 EPS $(0.84) Misses $(0.67) Estimate, Sales $194.515M Beat $177.937M Estimate

Benzinga Earnings
·
May 08

BRIEF-BridgeBio Pharma Q1 Net Income USD -166.555 Million

Reuters
·
May 08

BridgeBio Pharma Inc - Anvisa Approves Beyonttra (Acoramidis) for Attr-Cm in Brazil on May 4, 2026

THOMSON REUTERS
·
May 08

BridgeBio Pharma Q1 EPS USD -0.84

THOMSON REUTERS
·
May 08

BridgeBio Pharma Inc - Authorizes Share Repurchase Program of up to $500 Mln

THOMSON REUTERS
·
May 08

BridgeBio Pharma Inc - Q1 Total Revenues $194.5 Mln

THOMSON REUTERS
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

BridgeBio receives regulatory approval in Brazil for Beyonttra

TIPRANKS
·
May 07

BridgeBio participates in BofA Securities Health Care Conference fireside chat

Reuters
·
May 07

Brazil regulator ANVISA approves BridgeBio Beyonttra for ATTR cardiomyopathy treatment

Reuters
·
May 06

Beyonttra™ (Acoramidis), the First Near-Complete Ttr Stabilizer (≥90%), Approved by Anvisa to Treat Attr-Cm in Brazil

THOMSON REUTERS
·
May 06

BridgeBio Oncology Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview

Reuters
·
May 06

BridgeBio to present Phase 3 CALIBRATE primary results for encaleret at 2026 ECE

Reuters
·
May 05

BridgeBio CAO Maricel Apuli disposes 2,000 shares worth $143,160

Reuters
·
May 05

BridgeBio presents new Phase 3 acoramidis ATTR-CM outcomes data at ESC-HF 2026

Reuters
·
May 04

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), BridgeBio Pharma (BBIO)

TIPRANKS
·
May 03